Common dose adjustments in the phase III trial

Adverse reactions leading to dose adjustments in non-small cell lung cancer Dosing summary for all 3 indications

Common dose adjustments in the phase III trial

Adverse reactions leading to dose adjustments in non-small cell lung cancer nsclc-dose-mod

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

INDICATION

ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.